An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center [Yüksek hacimli bir kanser merkezinde uterin leiomyosarkomlu 37 olgunun analizi]

Basit Öğe Kaydı
dc.contributor.authorSolmaz U.
dc.contributor.authorDereli L.
dc.contributor.authorDemirtaş G.S.
dc.contributor.authorEkin A.
dc.contributor.authorMat E.
dc.contributor.authorGezer C.
dc.contributor.authorHasdemir P.S.
dc.contributor.authorSayhan S.
dc.contributor.authorSancı M.
dc.contributor.authorAşkar N.
dc.date.accessioned2019-10-26T21:26:05Z
dc.date.available2019-10-26T21:26:05Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and prognosis of uterine leiomyosarcoma (ULMS). Materials and Methods: All patients with ULMS who were treated between January 1998 and October 2012 were retrospectively reviewed. A total of 37 women who met the inclusion criteria were included in the present study. Univariate and multivariate analyses were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS). Results: The majority of patients had stage 1 disease (IA, n=9 (24.3%); IB, n=23 (62.1%)). All patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Additionally, only pelvic, and pelvic plus para-aortic lymphadenectomy was performed in 5 (13.5%) and 8 (21.6%) women, respectively. Adjuvant treatment was administered to 27 (72.9%) patients. Patients who did not receive adjuvant therapy had stage 1 disease. Recurrences occurred in 5 (13.5%) patients. The median follow-up period was 71 months (range 1-158 months). The 5-year PFS and OS rates were 68% and 74%, for all patients. The 5-year OS rates for women with stage 1 and ? stage 2 disease were 82% and 27%, respectively. Multivariate analysis confirmed stage 1 disease as the only independent predictor of both PFS (Odds ratio (OR) 10.955, 95% confidence interval (CI) 1.686-71.181, (p=0.012)) and OS (OR 57.429, 95% CI 3.287-1003.269, (p=0.006)). Conclusions: Extensive surgery is not associated with prognosis and stage 1 disease is the only independent good prognostic factor for survival in patients with ULMS. © 2015, Turkish Society of Obstetrics and Gynecology. All rights reserved.en_US
dc.identifier.doi10.4274/tjod.33602
dc.identifier.endpage163en_US
dc.identifier.issn1307699X
dc.identifier.issn1307-699Xen_US
dc.identifier.issue3en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage158en_US
dc.identifier.urihttps://doi.org/10.4274/tjod.33602
dc.identifier.urihttps://hdl.handle.net/11454/17316
dc.identifier.volume12en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkish Society of Obstetrics and Gynecologyen_US
dc.relation.ispartofTurk Jinekoloji ve Obstetrik Dernegi Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLymph node dissectionen_US
dc.subjectStageen_US
dc.subjectSurvivalen_US
dc.subjectUterine leiomyosarcomaen_US
dc.titleAn analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center [Yüksek hacimli bir kanser merkezinde uterin leiomyosarkomlu 37 olgunun analizi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu